Benjamin Berinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Berinson has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Holger Rohde
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf
15 shared publications Martin Aepfelbacher
12 shared publicationsMartin Christner
10 shared publicationsNicole Degel-Brossmann
Department of Microbiology, Institute for Medical Microbiology, Virology and Hygiene,Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
5 shared publicationsAnna Both
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4 shared publicationsKonstantin Tanida
4 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 74
First human isolation of Gibbsiella quercinecans associated with infection - significance and relevance
- 8 October 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 74
Open AccessFirst human isolation of Gibbsiella quercinecans associated with infection - significance and relevance
- Open Access
Heteroresistance to first-line β-lactams among Gram-negative bloodstream isolates reported susceptible by standard-of-care testing: a prospective two-centre study across a high- and a low-resistance setting
Summary: Background: Antibiotic heteroresistance (HR) — a resistant subpopulation within a clonal isolate reported susceptible by routine testing — can drive unexplained treatment failure and on-treatment emergence of resistance, yet prospective prevalence data for first-line β-lactams in Gram-negative bloodstream infection are lacking. We assessed the prevalence and genomic basis of HR to piperacillin, piperacillin/tazobactam, or meropenem among bloodstream isolates reported susceptible by standard-of-care testing. Methods: In this prospective two-centre prevalence study we screened consecutive monomicrobial Gram-negative positive blood cultures at the University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, and the Fondazione Policlinico Universitario A. Gemelli IRCCS (FPG), Rome, Italy. Enterobacterales and Pseudomonadales reported susceptible by standard-of-care AST were allocated to one investigated beta-lactam (piperacillin, piperacillin/tazobactam or meropenem) according to their routine susceptibility phenotype (Vitek2), and entered a two-tier phenotypic workflow: an agar filter at 0.5x the EUCAST breakpoint in triplicate, followed - if positive - by population analysis profiling (PAP) up to 4x the breakpoint. Heteroresistance was defined as a clonal resistant subpopulation at a frequency of at least 0.5×10 -6 surviving in the 4x breakpoint zone. Prevalence was estimated with Wilson-score 95% CIs and compared between centres with Fisher’s exact test. Confirmed heteroresistant isolates and their paired susceptible bulk populations underwent short- and long-read whole-genome sequencing, and each resistant/susceptible pair was tested for tandem gene amplification, differential subclonal point variants and structural variation. Findings: 279 isolates were screened (93 at UKE, 186 at Gemelli). The 0.5x breakpoint filter was positive in 22 of 93 isolates (23.7%) at UKE and 66 of 186 (35.5%) at Gemelli. PAP confirmed heteroresistance in 6 of 93 isolates at UKE (6.5%, 95% CI 3.0-13.4) and 27 of 186 at Gemelli (14.5%, 10.2-20.3), a pooled prevalence of 33 of 279 (11.8%, 8.5-16.1); the between-centre difference did not reach significance (Fisher’s exact test p=0.051). Heteroresistance was essentially confined to piperacillin/tazobactam: 32 of 150 isolates screened against piperacillin/tazobactam were heteroresistant (21.3%, 15.5-28.6), versus 1 of 71 for piperacillin (1.4%) and 0 of 58 for meropenem. Escherichia coli accounted for 17 of the 33 heteroresistant isolates. In the resistant/susceptible pairs sequenced to date a candidate mechanism was resolved in 18: 13 carried a tandem amplification of a beta-lactamase locus (copy-number ratio 2.4-33.0; amplified units 5-136 kb, most often plasmid-borne and centred on blaTEM-1, blaCTX-M or blaOXA-1 ), and 5 carried point variants in the AmpC circuit ( ampD, ampR, dacB/PBP4 ) or in efflux components, three of them fixed loss- or gain-of-function changes and three subclonal. Interpretation: Roughly one in eight Gram-negative bloodstream isolates called susceptible to a first-line beta-lactam harboured a resistant subpopulation, and the burden fell almost entirely on piperacillin/tazobactam - the agent most often used empirically in this setting. The dominant genomic substrate was unstable amplification of an existing beta-lactamase gene rather than acquisition of a new resistance determinant, which explains why the phenotype is reversible, invisible to AST and, in principle, quantifiable by copy-number assays at the point of care. Funding: Part of these data were presented at ESCMID Global 2026, and D.S. received an ESCMID travel grant in support of that presentation. Research in context: Evidence before this study: Beta-lactam heteroresistance in Gram-negative bacteria has been characterised mainly in reference collections and in single-species surveys, where unstable tandem amplification of resistance genes was identified as the principal mechanism and shown to be reversible and frequently missed by routine AST. HR has been linked to unexplained treatment failure, shown to cause discrepant susceptibility results, and — in a recent report — demonstrated to underlie within-patient conversion from susceptible to resistant during therapy. However, prospective, multicentre prevalence data for HR to the first-line β-lactams used empirically in Gram-negative bloodstream infection (piperacillin, piperacillin/tazobactam, meropenem), restricted to isolates that routine AST reports as susceptible, and paired with genome-resolved mechanisms, were lacking. Added value of this study: To our knowledge this is the first prospective, multicentre study to quantify PAP-confirmed HR to first-line β-lactams specifically among Gram-negative bloodstream isolates categorised as susceptible by standard-of-care AST, and to pair that prevalence with complete (short-plus long-read) genome analysis of clonal resistant/susceptible pairs. We show that HR is common (6.45% at UKE, 14.97% at FPG; pooled 12.1%, 34/280), that it is almost entirely confined to piperacillin/tazobactam (33 of 34 HR isolates; 21.9% of piperacillin/tazobactam-screened isolates versus ≤1.4% for piperacillin and none for meropenem), and that among 33 evaluable clonal pairs a genomic lesion is identifiable in 42·4%, dominated by unstable tandem amplification of β-lactamase-bearing blocks (11/33; 3·5–36×), with de-repressing mutations in efflux and AmpC regulators accounting for the remainder. Two further contributions are methodological. First, nearly half the pairs (45·5%) are negative on both genomic arms, placing non-genetic heteroresistance on the same footing as amplification rather than treating it as an exception. Second, resequencing the same isolates reproduced every amplification call but not its magnitude (+20% to −55%), showing that amplicon copy number is a snapshot of subclone frequency rather than a strain attribute — a constraint that any copy-number-based diagnostic must accommodate. Resistant subpopulations carried no evident fitness cost. Implications of all the available evidence: AST-susceptible Gram-negative bloodstream isolates not infrequently harbour resistant subpopulations that current diagnostics cannot see but that can expand under first-line β-lactam therapy. Together with evidence that pre-existing HR can drive on-treatment resistance, our findings argue for the development of rapid, target-specific molecular assays (e.g. copy-number digital PCR) to detect HR in the diagnostic laboratory — read as quantitative, condition-dependent measurements rather than as fixed strain attributes — and for a prospective clinical study to determine whether breakpoint-crossing HR predicts therapeutic failure in Gram-negative bloodstream infection.
Open AccessHeteroresistance to first-line β-lactams among Gram-negative bloodstream isolates reported susceptible by standard-of-care testing: a prospective two-centre study across a high- and a low-resistance setting
Summary: Background: Antibiotic heteroresistance (HR) — a resistant subpopulation within a clonal isolate reported susceptible by routine testing — can drive unexplained treatment failure and on-treatment emergence of resistance, yet prospective prevalence data for first-line β-lactams in Gram-negative bloodstream infection are lacking. We assessed the prevalence and genomic basis of HR to piperacillin, piperacillin/tazobactam, or meropenem among bloodstream isolates reported susceptible by standard-of-care testing. Methods: In this prospective two-centre prevalence study we screened consecutive monomicrobial Gram-negative positive blood cultures at the University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, and the Fondazione Policlinico Universitario A. Gemelli IRCCS (FPG), Rome, Italy. Enterobacterales and Pseudomonadales reported susceptible by standard-of-care AST were allocated to one investigated beta-lactam (piperacillin, piperacillin/tazobactam or meropenem) according to their routine susceptibility phenotype (Vitek2), and entered a two-tier phenotypic workflow: an agar filter at 0.5x the EUCAST breakpoint in triplicate, followed - if positive - by population analysis profiling (PAP) up to 4x the breakpoint. Heteroresistance was defined as a clonal resistant subpopulation at a frequency of at least 0.5×10 -6 surviving in the 4x breakpoint zone. Prevalence was estimated with Wilson-score 95% CIs and compared between centres with Fisher’s exact test. Confirmed heteroresistant isolates and their paired susceptible bulk populations underwent short- and long-read whole-genome sequencing, and each resistant/susceptible pair was tested for tandem gene amplification, differential subclonal point variants and structural variation. Findings: 279 isolates were screened (93 at UKE, 186 at Gemelli). The 0.5x breakpoint filter was positive in 22 of 93 isolates (23.7%) at UKE and 66 of 186 (35.5%) at Gemelli. PAP confirmed heteroresistance in 6 of 93 isolates at UKE (6.5%, 95% CI 3.0-13.4) and 27 of 186 at Gemelli (14.5%, 10.2-20.3), a pooled prevalence of 33 of 279 (11.8%, 8.5-16.1); the between-centre difference did not reach significance (Fisher’s exact test p=0.051). Heteroresistance was essentially confined to piperacillin/tazobactam: 32 of 150 isolates screened against piperacillin/tazobactam were heteroresistant (21.3%, 15.5-28.6), versus 1 of 71 for piperacillin (1.4%) and 0 of 58 for meropenem. Escherichia coli accounted for 17 of the 33 heteroresistant isolates. In the resistant/susceptible pairs sequenced to date a candidate mechanism was resolved in 18: 13 carried a tandem amplification of a beta-lactamase locus (copy-number ratio 2.4-33.0; amplified units 5-136 kb, most often plasmid-borne and centred on blaTEM-1, blaCTX-M or blaOXA-1 ), and 5 carried point variants in the AmpC circuit ( ampD, ampR, dacB/PBP4 ) or in efflux components, three of them fixed loss- or gain-of-function changes and three subclonal. Interpretation: Roughly one in eight Gram-negative bloodstream isolates called susceptible to a first-line beta-lactam harboured a resistant subpopulation, and the burden fell almost entirely on piperacillin/tazobactam - the agent most often used empirically in this setting. The dominant genomic substrate was unstable amplification of an existing beta-lactamase gene rather than acquisition of a new resistance determinant, which explains why the phenotype is reversible, invisible to AST and, in principle, quantifiable by copy-number assays at the point of care. Funding: Part of these data were presented at ESCMID Global 2026, and D.S. received an ESCMID travel grant in support of that presentation. Research in context: Evidence before this study: Beta-lactam heteroresistance in Gram-negative bacteria has been characterised mainly in reference collections and in single-species surveys, where unstable tandem amplification of resistance genes was identified as the principal mechanism and shown to be reversible and frequently missed by routine AST. HR has been linked to unexplained treatment failure, shown to cause discrepant susceptibility results, and — in a recent report — demonstrated to underlie within-patient conversion from susceptible to resistant during therapy. However, prospective, multicentre prevalence data for HR to the first-line β-lactams used empirically in Gram-negative bloodstream infection (piperacillin, piperacillin/tazobactam, meropenem), restricted to isolates that routine AST reports as susceptible, and paired with genome-resolved mechanisms, were lacking. Added value of this study: To our knowledge this is the first prospective, multicentre study to quantify PAP-confirmed HR to first-line β-lactams specifically among Gram-negative bloodstream isolates categorised as susceptible by standard-of-care AST, and to pair that prevalence with complete (short-plus long-read) genome analysis of clonal resistant/susceptible pairs. We show that HR is common (6.45% at UKE, 14.97% at FPG; pooled 12.1%, 34/280), that it is almost entirely confined to piperacillin/tazobactam (33 of 34 HR isolates; 21.9% of piperacillin/tazobactam-screened isolates versus ≤1.4% for piperacillin and none for meropenem), and that among 33 evaluable clonal pairs a genomic lesion is identifiable in 42·4%, dominated by unstable tandem amplification of β-lactamase-bearing blocks (11/33; 3·5–36×), with de-repressing mutations in efflux and AmpC regulators accounting for the remainder. Two further contributions are methodological. First, nearly half the pairs (45·5%) are negative on both genomic arms, placing non-genetic heteroresistance on the same footing as amplification rather than treating it as an exception. Second, resequencing the same isolates reproduced every amplification call but not its magnitude (+20% to −55%), showing that amplicon copy number is a snapshot of subclone frequency rather than a strain attribute — a constraint that any copy-number-based diagnostic must accommodate. Resistant subpopulations carried no evident fitness cost. Implications of all the available evidence: AST-susceptible Gram-negative bloodstream isolates not infrequently harbour resistant subpopulations that current diagnostics cannot see but that can expand under first-line β-lactam therapy. Together with evidence that pre-existing HR can drive on-treatment resistance, our findings argue for the development of rapid, target-specific molecular assays (e.g. copy-number digital PCR) to detect HR in the diagnostic laboratory — read as quantitative, condition-dependent measurements rather than as fixed strain attributes — and for a prospective clinical study to determine whether breakpoint-crossing HR predicts therapeutic failure in Gram-negative bloodstream infection.
- Open Access
- 30 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0395625
Comparative evaluation of EUCAST RAST and QuickMIC for rapid antimicrobial susceptibility testing of carbapenem-resistant organisms directly from positive blood cultures
Rapid availability of phenotypic susceptibility results is crucial for the timely detection of multidrug-resistant Gram-negative organisms. Several novel methods have been introduced that enable direct antimicrobial susceptibility testing (AST) from positive blood cultures. This study aimed to assess the analytical performance of the agar diffusion-based EUCAST rapid AST (RAST) method and the automated QuickMIC system using a challenging collection of highly resistant Gram-negative organisms. One hundred one Gram-negative bacteria ( Escherichia coli , n = 24; Klebsiella pneumoniae , n = 22; Acinetobacter baumannii , n = 30; and Pseudomonas aeruginosa , n = 25) were spiked into blood cultures and processed according to the respective AST protocols. Broth microdilution (BMD) was performed as the reference method. Time to result (TTR), categorical agreement (CA), and essential agreement (EA) with BMD were evaluated. Boruta analysis was applied to identify genetic determinants associated with AST errors. Overall TTR for QuickMIC was 3 h 44 min with a CA of 86.2% and an EA of 92.3% for Enterobacteriaceae and 97.0% for non-fermenters. Overall CA of RAST ranged from 90.7% to 93.7% across reading time points. Overall, very major discrepancy rates were low (QuickMIC, n = 0.7%, and RAST, n = 0.1%). Presence of NDM-5 and KPC was most frequently associated with errors for QuickMIC and EUCAST RAST, respectively. Both rapid AST approaches yielded rapid and robust results in this diverse and highly resistant bacterial study population. These findings underscore the potential of rapid AST methods to facilitate timely optimization of antimicrobial therapy in bloodstream infections, even in the context of extensively drug-resistant pathogens. IMPORTANCE: Accurate antimicrobial susceptibility testing (AST) is essential for stewardship and effective therapy, especially as rising antimicrobial resistance increases the risk of empiric treatment failure. Traditional AST methods are limited by slow turnaround times, creating a need for rapid alternatives. This study evaluated the diagnostic accuracy of two rapid AST (RAST) methods—EUCAST RAST and QuickMIC—using 101 genetically characterized, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii tested directly from positive blood cultures. Broth microdilution served as the reference. Both rapid assays provided results within 3.5–6 h and demonstrated high categorical and essential agreement with few very major discrepancies. Incorrect results were more common in isolates harboring NDM-5 and KPC carbapenemases. Overall, the findings support EUCAST RAST and QuickMIC as reliable tools for challenging resistant pathogens and highlight their potential to enable earlier detection of carbapenem-resistant phenotypes and more timely initiation of appropriate, last-resort antimicrobial therapy.
- 30 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0395625
Open AccessComparative evaluation of EUCAST RAST and QuickMIC for rapid antimicrobial susceptibility testing of carbapenem-resistant organisms directly from positive blood cultures
Rapid availability of phenotypic susceptibility results is crucial for the timely detection of multidrug-resistant Gram-negative organisms. Several novel methods have been introduced that enable direct antimicrobial susceptibility testing (AST) from positive blood cultures. This study aimed to assess the analytical performance of the agar diffusion-based EUCAST rapid AST (RAST) method and the automated QuickMIC system using a challenging collection of highly resistant Gram-negative organisms. One hundred one Gram-negative bacteria ( Escherichia coli , n = 24; Klebsiella pneumoniae , n = 22; Acinetobacter baumannii , n = 30; and Pseudomonas aeruginosa , n = 25) were spiked into blood cultures and processed according to the respective AST protocols. Broth microdilution (BMD) was performed as the reference method. Time to result (TTR), categorical agreement (CA), and essential agreement (EA) with BMD were evaluated. Boruta analysis was applied to identify genetic determinants associated with AST errors. Overall TTR for QuickMIC was 3 h 44 min with a CA of 86.2% and an EA of 92.3% for Enterobacteriaceae and 97.0% for non-fermenters. Overall CA of RAST ranged from 90.7% to 93.7% across reading time points. Overall, very major discrepancy rates were low (QuickMIC, n = 0.7%, and RAST, n = 0.1%). Presence of NDM-5 and KPC was most frequently associated with errors for QuickMIC and EUCAST RAST, respectively. Both rapid AST approaches yielded rapid and robust results in this diverse and highly resistant bacterial study population. These findings underscore the potential of rapid AST methods to facilitate timely optimization of antimicrobial therapy in bloodstream infections, even in the context of extensively drug-resistant pathogens. IMPORTANCE: Accurate antimicrobial susceptibility testing (AST) is essential for stewardship and effective therapy, especially as rising antimicrobial resistance increases the risk of empiric treatment failure. Traditional AST methods are limited by slow turnaround times, creating a need for rapid alternatives. This study evaluated the diagnostic accuracy of two rapid AST (RAST) methods—EUCAST RAST and QuickMIC—using 101 genetically characterized, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii tested directly from positive blood cultures. Broth microdilution served as the reference. Both rapid assays provided results within 3.5–6 h and demonstrated high categorical and essential agreement with few very major discrepancies. Incorrect results were more common in isolates harboring NDM-5 and KPC carbapenemases. Overall, the findings support EUCAST RAST and QuickMIC as reliable tools for challenging resistant pathogens and highlight their potential to enable earlier detection of carbapenem-resistant phenotypes and more timely initiation of appropriate, last-resort antimicrobial therapy.
- Open Access
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0398425
IS-Pro-based pathogen detection in explanted heart valves of suspected endocarditis patients
Accurate pathogen identification in infective endocarditis (IE) is limited, particularly in culture-negative cases. This study evaluated the performance of the Molecular Culture ID (MC-ID) assay in heart valve specimens from patients with suspected IE. Fifty-seven valve specimens from patients with suspected IE were analyzed using conventional culture, 16S/18S rDNA sequencing (SepsiTest, Molzym, Germany), the Biofire Joint Infection Panel (BJP; bioMérieux, Marcy l'Étoile, France), and MC-ID, with previously reported results as comparators. Twelve specimens (21.1%) were culture-positive, and 45 (78.9%) were culture-negative. MC-ID showed 83.3% positive agreement and 44.4% negative agreement with culture, achieving species-level concordance in 8/12 cases. Three culture-positive/MC-ID-negative results reflected organisms outside the assay’s detection range or limited taxonomic resolution. MC-ID detected pathogens in 25/45 (55.5%) culture-negative specimens; 21 were corroborated by PCR and/or BJP. Discrepancies largely reflected polymicrobial infections or taxonomic resolution limits. MC-ID identified pathogens in four PCR-/BJP-negative specimens, of which three likely were of clinical significance. MC-ID was negative in two culture-negative, PCR-/BJP-positive specimens. MC-ID can improve pathogen detection in both culture-positive and culture-negative IE, complementing conventional and molecular diagnostics and providing a comprehensive microbiological assessment in suspected IE cases. IMPORTANCE: Infective endocarditis (IE) remains difficult to diagnose, especially when blood and tissue cultures fail to identify a pathogen. Accurate organism detection is essential for guiding targeted therapy and reducing reliance on broad-spectrum antibiotics. This study shows that the Molecular Culture ID (MC-ID) assay markedly improves diagnostic yield in culture-negative valve specimens, frequently identifying pathogens missed by conventional and molecular tests. MC-ID also clarifies cases complicated by polymicrobial infection or limited taxonomic resolution, providing species-level or clinically actionable identification in many instances. By complementing existing diagnostic methods and expanding detection beyond their constraints, MC-ID offers a more comprehensive microbiological assessment of suspected endocarditis. Its integration into diagnostic workflows has the potential to enhance clinical decision-making and improve management of this high-risk condition.
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0398425
Open AccessIS-Pro-based pathogen detection in explanted heart valves of suspected endocarditis patients
Accurate pathogen identification in infective endocarditis (IE) is limited, particularly in culture-negative cases. This study evaluated the performance of the Molecular Culture ID (MC-ID) assay in heart valve specimens from patients with suspected IE. Fifty-seven valve specimens from patients with suspected IE were analyzed using conventional culture, 16S/18S rDNA sequencing (SepsiTest, Molzym, Germany), the Biofire Joint Infection Panel (BJP; bioMérieux, Marcy l'Étoile, France), and MC-ID, with previously reported results as comparators. Twelve specimens (21.1%) were culture-positive, and 45 (78.9%) were culture-negative. MC-ID showed 83.3% positive agreement and 44.4% negative agreement with culture, achieving species-level concordance in 8/12 cases. Three culture-positive/MC-ID-negative results reflected organisms outside the assay’s detection range or limited taxonomic resolution. MC-ID detected pathogens in 25/45 (55.5%) culture-negative specimens; 21 were corroborated by PCR and/or BJP. Discrepancies largely reflected polymicrobial infections or taxonomic resolution limits. MC-ID identified pathogens in four PCR-/BJP-negative specimens, of which three likely were of clinical significance. MC-ID was negative in two culture-negative, PCR-/BJP-positive specimens. MC-ID can improve pathogen detection in both culture-positive and culture-negative IE, complementing conventional and molecular diagnostics and providing a comprehensive microbiological assessment in suspected IE cases. IMPORTANCE: Infective endocarditis (IE) remains difficult to diagnose, especially when blood and tissue cultures fail to identify a pathogen. Accurate organism detection is essential for guiding targeted therapy and reducing reliance on broad-spectrum antibiotics. This study shows that the Molecular Culture ID (MC-ID) assay markedly improves diagnostic yield in culture-negative valve specimens, frequently identifying pathogens missed by conventional and molecular tests. MC-ID also clarifies cases complicated by polymicrobial infection or limited taxonomic resolution, providing species-level or clinically actionable identification in many instances. By complementing existing diagnostic methods and expanding detection beyond their constraints, MC-ID offers a more comprehensive microbiological assessment of suspected endocarditis. Its integration into diagnostic workflows has the potential to enhance clinical decision-making and improve management of this high-risk condition.
- Open Access
Comparative evaluation of EUCAST RAST and QuickMIC for rapid susceptibility testing of carbapenem-resistant organisms directly from positive blood cultures
Objective: The rapid availability of phenotypic antimicrobial susceptibility results is crucial for the timely detection of multidrug-resistant Gram-negative organisms and for guiding optimized treatment strategies. Recently, novel methods have been introduced that enable direct antimicrobial susceptibility testing (AST) from positive blood cultures. However, their performance has not yet been systematically compared in head-to-head evaluations. This study aimed to assess the analytical performance of two rapid AST approaches—the agar diffusion–based EUCAST rapid AST (RAST) method and the automated QuickMIC system—using a challenging collection of highly resistant Gram-negative organisms. Methods: A total of 101 Gram-negative bacteria ( Escherichia coli , n = 24; Klebsiella pneumoniae , n = 22; Acinetobacter baumannii , n = 30; Pseudomonas aeruginosa , n = 25) were spiked into blood cultures and processed according to the respective AST workflows. Broth microdilution (BMD) was performed from pure cultures as the reference method. Time to result (TTR), categorical agreement (CA), and essential agreement (EA) with BMD were evaluated. Boruta analysis was applied to identify genetic determinants associated with AST errors. Results: Overall TTR for QuickMIC was 3 h 44 min with a CA of 86.2%, an EA of 92.3 % for Enterobacteriaceae and 97.0 % for non-fermenters. Overall CA of RAST ranged from 90.7%-93.7% across reading time points. Overall, very major discrepancy rates were low (QuickMIC n=0.7%, RAST n=0.1%). Presence of NDM-5 and KPC was most frequently associated with errors for QuickMIC and EUCAST RAST, respectively. Conclusions: Both rapid AST approaches yielded robust results in this diverse and highly resistant bacterial study population, directly from positive blood cultures, with a short turnaround time. These findings underscore the potential of rapid AST methods to facilitate timely optimization of antimicrobial therapy in bloodstream infections, even in the context of extensively drug-resistant pathogens. Importance: Accurate antimicrobial susceptibility testing (AST) is essential for stewardship and effective therapy, especially as rising antimicrobial resistance increases the risk of empiric treatment failure. Traditional AST methods are limited by slow turnaround times, creating a need for rapid alternatives. This study evaluated the diagnostic accuracy of two rapid AST methods—EUCAST RAST and QuickMIC—using 101 genetically characterized, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii tested directly from positive blood cultures. Broth microdilution served as the reference. Both rapid assays provided results within 3.5–6 hours and demonstrated high categorical and essential agreement with few very major discrepancies. Incorrect results were more common in isolates harboring NDM-5 and KPC carbapenemases. Overall, the findings support EUCAST RAST and QuickMIC as reliable tools for challenging resistant pathogens and highlight their potential to enable earlier detection of carbapenem-resistant phenotypes and more timely initiation of appropriate, last-resort antimicrobial therapy.
Open AccessComparative evaluation of EUCAST RAST and QuickMIC for rapid susceptibility testing of carbapenem-resistant organisms directly from positive blood cultures
Objective: The rapid availability of phenotypic antimicrobial susceptibility results is crucial for the timely detection of multidrug-resistant Gram-negative organisms and for guiding optimized treatment strategies. Recently, novel methods have been introduced that enable direct antimicrobial susceptibility testing (AST) from positive blood cultures. However, their performance has not yet been systematically compared in head-to-head evaluations. This study aimed to assess the analytical performance of two rapid AST approaches—the agar diffusion–based EUCAST rapid AST (RAST) method and the automated QuickMIC system—using a challenging collection of highly resistant Gram-negative organisms. Methods: A total of 101 Gram-negative bacteria ( Escherichia coli , n = 24; Klebsiella pneumoniae , n = 22; Acinetobacter baumannii , n = 30; Pseudomonas aeruginosa , n = 25) were spiked into blood cultures and processed according to the respective AST workflows. Broth microdilution (BMD) was performed from pure cultures as the reference method. Time to result (TTR), categorical agreement (CA), and essential agreement (EA) with BMD were evaluated. Boruta analysis was applied to identify genetic determinants associated with AST errors. Results: Overall TTR for QuickMIC was 3 h 44 min with a CA of 86.2%, an EA of 92.3 % for Enterobacteriaceae and 97.0 % for non-fermenters. Overall CA of RAST ranged from 90.7%-93.7% across reading time points. Overall, very major discrepancy rates were low (QuickMIC n=0.7%, RAST n=0.1%). Presence of NDM-5 and KPC was most frequently associated with errors for QuickMIC and EUCAST RAST, respectively. Conclusions: Both rapid AST approaches yielded robust results in this diverse and highly resistant bacterial study population, directly from positive blood cultures, with a short turnaround time. These findings underscore the potential of rapid AST methods to facilitate timely optimization of antimicrobial therapy in bloodstream infections, even in the context of extensively drug-resistant pathogens. Importance: Accurate antimicrobial susceptibility testing (AST) is essential for stewardship and effective therapy, especially as rising antimicrobial resistance increases the risk of empiric treatment failure. Traditional AST methods are limited by slow turnaround times, creating a need for rapid alternatives. This study evaluated the diagnostic accuracy of two rapid AST methods—EUCAST RAST and QuickMIC—using 101 genetically characterized, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii tested directly from positive blood cultures. Broth microdilution served as the reference. Both rapid assays provided results within 3.5–6 hours and demonstrated high categorical and essential agreement with few very major discrepancies. Incorrect results were more common in isolates harboring NDM-5 and KPC carbapenemases. Overall, the findings support EUCAST RAST and QuickMIC as reliable tools for challenging resistant pathogens and highlight their potential to enable earlier detection of carbapenem-resistant phenotypes and more timely initiation of appropriate, last-resort antimicrobial therapy.
- Open Access
- 2 September 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (9) , e0126325
Comparative evaluation of Biofire Joint Infection Panel, Sepsitest 16S/18S rDNA PCR, and culture to identify microorganisms in explanted heart valves
Infective endocarditis (IE) is a major life-threatening disease. However, the inability to identify the causative pathogen using conventional microbiological cultures jeopardizes the choice of optimal antibiotic therapy. Culture-independent molecular techniques for pathogen detection may overcome this challenge. Here, two molecular tests (16S/18S rDNA assay [SepsiTest, Molzym, Germany]; Biofire Joint Infection Panel [BJP, bioMérieux, Marcy l’Étoile, France]) were analyzed for their ability to detect pathogens in a series of 100 explanted heart valves. In total, at least one pathogen was detected in 67/100 specimens by one or more methods, and 33/100 specimens were negative in all three assays. Overall, valve-culture had an inferior sensitivity (39.4%), compared to 16S/18S rDNA PCR (90.9%) and the BJP (83.1% [all organisms], 98.2% [on-panel organisms only]). In culture-negative cases, 35 and 32 additional pathogens were identified by 16S/18S rDNA PCR and BJP, respectively. In five culture- and 16S/18S rDNA assay-negative cases, BJP identified correctly additional pathogens. False-positive results were observed in one (16S/18S rDNA PCR) and two (BJP) cases, respectively. In conclusion, both culture-independent assays proved to be reliable and increased the diagnostic yield compared to culture. In general, false negatives (i.e., off-panel pathogens in BJP) and false positives require careful clinical evaluation of results from culture-independent techniques. Diagnostic stewardship is essential to guide the optimal use of molecular techniques in the work-up of infective endocarditis. IMPORTANCE: Infective endocarditis (IE) therapy must be guided by the identification of the causative pathogen. Microbiological cultures, however, remain negative in a significant number of cases, jeopardizing the choice of optimal anti-infective treatment. This study evaluated the ability of two independent molecular tests (16/18S rDNA PCR, syndromic panel PCR [Biofire JI panel]) to overcome limitations of conventional microbiological approaches to detect microorganisms from explanted heart valve tissues. Both assays proved to have a greater sensitivity compared to conventional culture, and PCR and BJP identified a pathogen in 35 and 32 out of 74 culture negative IE cases, additional pathogens, respectively. The study highlights the great importance of culture-independent approaches to pathogen detection in IE and guides the choice of the optimal assay using diagnostic stewardship interventions.
- 2 September 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (9) , e0126325
Open AccessComparative evaluation of Biofire Joint Infection Panel, Sepsitest 16S/18S rDNA PCR, and culture to identify microorganisms in explanted heart valves
Infective endocarditis (IE) is a major life-threatening disease. However, the inability to identify the causative pathogen using conventional microbiological cultures jeopardizes the choice of optimal antibiotic therapy. Culture-independent molecular techniques for pathogen detection may overcome this challenge. Here, two molecular tests (16S/18S rDNA assay [SepsiTest, Molzym, Germany]; Biofire Joint Infection Panel [BJP, bioMérieux, Marcy l’Étoile, France]) were analyzed for their ability to detect pathogens in a series of 100 explanted heart valves. In total, at least one pathogen was detected in 67/100 specimens by one or more methods, and 33/100 specimens were negative in all three assays. Overall, valve-culture had an inferior sensitivity (39.4%), compared to 16S/18S rDNA PCR (90.9%) and the BJP (83.1% [all organisms], 98.2% [on-panel organisms only]). In culture-negative cases, 35 and 32 additional pathogens were identified by 16S/18S rDNA PCR and BJP, respectively. In five culture- and 16S/18S rDNA assay-negative cases, BJP identified correctly additional pathogens. False-positive results were observed in one (16S/18S rDNA PCR) and two (BJP) cases, respectively. In conclusion, both culture-independent assays proved to be reliable and increased the diagnostic yield compared to culture. In general, false negatives (i.e., off-panel pathogens in BJP) and false positives require careful clinical evaluation of results from culture-independent techniques. Diagnostic stewardship is essential to guide the optimal use of molecular techniques in the work-up of infective endocarditis. IMPORTANCE: Infective endocarditis (IE) therapy must be guided by the identification of the causative pathogen. Microbiological cultures, however, remain negative in a significant number of cases, jeopardizing the choice of optimal anti-infective treatment. This study evaluated the ability of two independent molecular tests (16/18S rDNA PCR, syndromic panel PCR [Biofire JI panel]) to overcome limitations of conventional microbiological approaches to detect microorganisms from explanted heart valve tissues. Both assays proved to have a greater sensitivity compared to conventional culture, and PCR and BJP identified a pathogen in 35 and 32 out of 74 culture negative IE cases, additional pathogens, respectively. The study highlights the great importance of culture-independent approaches to pathogen detection in IE and guides the choice of the optimal assay using diagnostic stewardship interventions.
- Open Access
Evaluation of a commercial 16S rDNA PCR assay (UMD-SelectNA, Molzym) for pathogen detection from cardiac tissue specimens
The detection of bacteria in cardiac tissue, vegetations, or explanted prosthetic valves using nucleic acid amplification tests, such as 16S rDNA amplicon sequencing (16S rDNA PCR), has been incorporated as pathologic criterion for definite infective endocarditis into the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis. To verify results from previous studies suggesting increased detection rates and to investigate the added diagnostic value of 16S rDNA PCR, we prospectively compared the diagnostic yield of a CE-IVD-marked 16S rDNA PCR assay to conventional culture (CC) in a large number of cardiac tissue samples, relating our findings to microbiological evidence from blood culture sampling and patient history. Over a seven-year period (2016-2023), 687 cardiac tissue samples were subjected to CC and 16S rDNA PCR. 16S rDNA PCR and CC yielded positive results in 326 (47.4 %) and 154 (22.4 %) samples, respectively. 136 (19.7 %) samples were concordantly tested positive. In 190 (27.7 %) and 18 (2.6 %) samples, a positive result was obtained only by PCR or CC. 343 (49.9 %) samples tested negative by both methods. In a case-based analysis of a subgroup of blood culture-confirmed IE (241 cases) and BC-negative non-IE cases (126 cases), 16S rDNA PCR yielded a diagnostic sensitivity and specificity of 74.7 % and 98.4 %, while CC yielded a sensitivity and specificity of 38.6 % and 99.2 %. In conclusion, the use of 16S rDNA PCR significantly increased the detection rate for bacteria in heart valve tissue. A notable proportion of the culture-negative samples contained pathogens that are generally not detectable by conventional culture. Therefore, supplementation of CC with 16S rDNA PCR is recommended for cardiac tissue samples, especially in case of blood culture-negative endocarditis.
Open AccessEvaluation of a commercial 16S rDNA PCR assay (UMD-SelectNA, Molzym) for pathogen detection from cardiac tissue specimens
The detection of bacteria in cardiac tissue, vegetations, or explanted prosthetic valves using nucleic acid amplification tests, such as 16S rDNA amplicon sequencing (16S rDNA PCR), has been incorporated as pathologic criterion for definite infective endocarditis into the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis. To verify results from previous studies suggesting increased detection rates and to investigate the added diagnostic value of 16S rDNA PCR, we prospectively compared the diagnostic yield of a CE-IVD-marked 16S rDNA PCR assay to conventional culture (CC) in a large number of cardiac tissue samples, relating our findings to microbiological evidence from blood culture sampling and patient history. Over a seven-year period (2016-2023), 687 cardiac tissue samples were subjected to CC and 16S rDNA PCR. 16S rDNA PCR and CC yielded positive results in 326 (47.4 %) and 154 (22.4 %) samples, respectively. 136 (19.7 %) samples were concordantly tested positive. In 190 (27.7 %) and 18 (2.6 %) samples, a positive result was obtained only by PCR or CC. 343 (49.9 %) samples tested negative by both methods. In a case-based analysis of a subgroup of blood culture-confirmed IE (241 cases) and BC-negative non-IE cases (126 cases), 16S rDNA PCR yielded a diagnostic sensitivity and specificity of 74.7 % and 98.4 %, while CC yielded a sensitivity and specificity of 38.6 % and 99.2 %. In conclusion, the use of 16S rDNA PCR significantly increased the detection rate for bacteria in heart valve tissue. A notable proportion of the culture-negative samples contained pathogens that are generally not detectable by conventional culture. Therefore, supplementation of CC with 16S rDNA PCR is recommended for cardiac tissue samples, especially in case of blood culture-negative endocarditis.
- Open Access
- 1 April 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (4) , e0223924
Prospective evaluation of real-world performance and clinical impact of the Biofire FilmArray joint infection panel
Limitations of culture-based diagnostic approaches in pathogen detection in joint infections (JI) can be overcome by amplification-based, molecular assays. Recently, a syndromic panel PCR (spPCR) assay (Biofire JI panel; BJA) was approved for pathogen identification from synovial fluid (SF). Here, the performance and the clinical impact of the BJA were assessed in comparison to standard of care diagnostics in a prospective cohort of patients presenting with symptoms consistent with JI. One hundred sixty-five synovial fluids underwent analysis using the BJA. The results were compared with culture-based diagnostics. Discrepant results were re-analyzed using species-specific PCRs or 16S-rDNA sequencing. Clinical data from patients were collected to evaluate the impact on patient management. Twenty-seven of 165 (16.3%) synovial fluid cultures grew bacterial pathogens. In 24/27 cases, the BJA results were concordant. In one case, the cultured pathogen was missed, but three additional pathogens were identified. In 11 culture-negative cases, BJA identified a pathogen. Mean turnaround time in culture-positive samples was 14:11 h and 35:17 h in BJA and culture, respectively. In 11 cases, antibiotic therapy was optimized, based on BJA results. This study demonstrates high sensitivity and specificity (96.3% and 97.8%, respectively) of BJA, as well as a shorter turnaround time than culture-based techniques (21 h faster). Based on analysis of clinical data, antibiotic therapy was optimized due to BJA results in 11 cases. Care must be taken, as important pathogens in prosthetic JI are not included in the panel, restricting its value here. IMPORTANCE: Pathogen detection is critical for targeted management of joint infections; however, cultural detection of pathogens can be challenging. The Biofire Joint Infection Assay (BJA) is a syndromic panel PCR test that allows culture-independent detection of 31 pathogens. The diagnostic performance and clinical impact were evaluated in a cohort of 160 patients with native and prosthetic joint infections. BJA detected concordant pathogens in 24 of 27 culture-positive cases and enabled the detection of additional pathogens in 11 patients. The time to result was significantly shorter than with standard culture-based diagnostics (14 vs 35 h), and BJA allowed optimization of therapy in 11 patients. The data show that BJA is a relevant addition to the diagnostic options for joint infections. Limitations result from incomplete detection of relevant pathogens, especially in prosthetic joint infections. The use of BJA in daily practice must therefore be accompanied by diagnostic stewardship measures.
- 1 April 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (4) , e0223924
Open AccessProspective evaluation of real-world performance and clinical impact of the Biofire FilmArray joint infection panel
Limitations of culture-based diagnostic approaches in pathogen detection in joint infections (JI) can be overcome by amplification-based, molecular assays. Recently, a syndromic panel PCR (spPCR) assay (Biofire JI panel; BJA) was approved for pathogen identification from synovial fluid (SF). Here, the performance and the clinical impact of the BJA were assessed in comparison to standard of care diagnostics in a prospective cohort of patients presenting with symptoms consistent with JI. One hundred sixty-five synovial fluids underwent analysis using the BJA. The results were compared with culture-based diagnostics. Discrepant results were re-analyzed using species-specific PCRs or 16S-rDNA sequencing. Clinical data from patients were collected to evaluate the impact on patient management. Twenty-seven of 165 (16.3%) synovial fluid cultures grew bacterial pathogens. In 24/27 cases, the BJA results were concordant. In one case, the cultured pathogen was missed, but three additional pathogens were identified. In 11 culture-negative cases, BJA identified a pathogen. Mean turnaround time in culture-positive samples was 14:11 h and 35:17 h in BJA and culture, respectively. In 11 cases, antibiotic therapy was optimized, based on BJA results. This study demonstrates high sensitivity and specificity (96.3% and 97.8%, respectively) of BJA, as well as a shorter turnaround time than culture-based techniques (21 h faster). Based on analysis of clinical data, antibiotic therapy was optimized due to BJA results in 11 cases. Care must be taken, as important pathogens in prosthetic JI are not included in the panel, restricting its value here. IMPORTANCE: Pathogen detection is critical for targeted management of joint infections; however, cultural detection of pathogens can be challenging. The Biofire Joint Infection Assay (BJA) is a syndromic panel PCR test that allows culture-independent detection of 31 pathogens. The diagnostic performance and clinical impact were evaluated in a cohort of 160 patients with native and prosthetic joint infections. BJA detected concordant pathogens in 24 of 27 culture-positive cases and enabled the detection of additional pathogens in 11 patients. The time to result was significantly shorter than with standard culture-based diagnostics (14 vs 35 h), and BJA allowed optimization of therapy in 11 patients. The data show that BJA is a relevant addition to the diagnostic options for joint infections. Limitations result from incomplete detection of relevant pathogens, especially in prosthetic joint infections. The use of BJA in daily practice must therefore be accompanied by diagnostic stewardship measures.
- Open Access
- 16 October 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (10) , e0045824
A multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections
Common phenotypic methods for antimicrobial susceptibility testing (AST) of bacteria are slow, labor intensive, and display considerable technical variability. The QuickMIC system provides rapid AST using a microfluidic linear gradient. Here, we evaluate the performance of QuickMIC at four different laboratories with regard to speed, precision, accuracy, and reproducibility in comparison to broth microdilution (BMD). Spiked ( n = 411) and clinical blood cultures ( n = 148) were tested with the QuickMIC Gram-negative panel and compared with BMD for the 12 on-panel antibiotics, and 10 defined strains were run at each site to measure reproducibility. Logistic and linear regression analysis was applied to explore factors affecting assay performance. The overall essential agreement and categorical agreement between QuickMIC and BMD were 95.6% and 96.0%, respectively. Very major error, major error, and minor error rates were 1.0%, 0.6%, and 2.4%, respectively. Inter-laboratory reproducibility between the sites was high at 98.9% using the acceptable standard of ±1 twofold dilution. The mean in-instrument analysis time overall was 3 h 13 min (SD: 29 min). Regression analysis indicated that QuickMIC is robust with regard to initial inoculum and delay time after blood culture positivity. We conclude that QuickMIC can be used to rapidly measure MIC directly from blood cultures in clinical settings with high reproducibility, precision, and accuracy. The microfluidics-generated linear gradient ensures high reproducibility between laboratories, thus allowing a high level of trust in MIC values from single testing, at the cost of reduced measurement range compared to BMD. IMPORTANCE: Increasing antimicrobial resistance underscores the need for new diagnostic solutions to guide therapy, but traditional antimicrobial susceptibility testing (AST) is often inadequate in time-critical diseases such as sepsis. This work presents a novel and rapid AST system with a rapid turnaround of results, which may help reduce the time to guided therapy, possibly allowing early de-escalation of broad-spectrum empirical therapy as well as rapid adjustments to treatments when coverage is lacking.
- 16 October 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (10) , e0045824
Open AccessA multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections
Common phenotypic methods for antimicrobial susceptibility testing (AST) of bacteria are slow, labor intensive, and display considerable technical variability. The QuickMIC system provides rapid AST using a microfluidic linear gradient. Here, we evaluate the performance of QuickMIC at four different laboratories with regard to speed, precision, accuracy, and reproducibility in comparison to broth microdilution (BMD). Spiked ( n = 411) and clinical blood cultures ( n = 148) were tested with the QuickMIC Gram-negative panel and compared with BMD for the 12 on-panel antibiotics, and 10 defined strains were run at each site to measure reproducibility. Logistic and linear regression analysis was applied to explore factors affecting assay performance. The overall essential agreement and categorical agreement between QuickMIC and BMD were 95.6% and 96.0%, respectively. Very major error, major error, and minor error rates were 1.0%, 0.6%, and 2.4%, respectively. Inter-laboratory reproducibility between the sites was high at 98.9% using the acceptable standard of ±1 twofold dilution. The mean in-instrument analysis time overall was 3 h 13 min (SD: 29 min). Regression analysis indicated that QuickMIC is robust with regard to initial inoculum and delay time after blood culture positivity. We conclude that QuickMIC can be used to rapidly measure MIC directly from blood cultures in clinical settings with high reproducibility, precision, and accuracy. The microfluidics-generated linear gradient ensures high reproducibility between laboratories, thus allowing a high level of trust in MIC values from single testing, at the cost of reduced measurement range compared to BMD. IMPORTANCE: Increasing antimicrobial resistance underscores the need for new diagnostic solutions to guide therapy, but traditional antimicrobial susceptibility testing (AST) is often inadequate in time-critical diseases such as sepsis. This work presents a novel and rapid AST system with a rapid turnaround of results, which may help reduce the time to guided therapy, possibly allowing early de-escalation of broad-spectrum empirical therapy as well as rapid adjustments to treatments when coverage is lacking.
- Open Access
A multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections
Objectives Common phenotypic methods for antibiotic susceptibility testing (AST) of bacteria are slow, labour intensive and displays considerable technical variability. The QuickMIC system provides rapid AST using a microfluidic linear gradient. Here we evaluate the performance of QuickMIC at four different laboratories with regards to speed, precision, accuracy, and reproducibility in comparison to broth microdilution (BMD). Methods Spiked blood cultures (n=411) and clinical blood cultures (n=148) were tested with the QuickMIC Gram negative (GN) panel and compared with BMD for the 12 on-panel antibiotics, and 10 defined strains were run at each site to measure reproducibility. Logistic and linear regression analysis was applied to explore factors affecting assay performance. Results The overall essential agreement (EA) and categorical agreement (CA) between QuickMIC and BMD were 95.6% and 96.0%, respectively. Very major error (VME), Major error (ME) and minor error (mE) rates were 1.0, 0.6 and 2.4%, respectively. Inter-laboratory reproducibility between the sites was high at 98.9% using the acceptable standard of ±1 log2 unit. The mean in-instrument analysis time overall was 3h 13 min (SD: 29 min). Regression analysis indicated that QuickMIC is robust with regards to initial inoculate and delay time after blood culture positivity. Conclusions We conclude that QuickMIC can be used to rapidly measure MIC directly from blood cultures in clinical settings, with a high reproducibility, precision, and accuracy. The microfluidics-generated linear gradient ensures high repeatability and reproducibility between laboratories, thus allowing a high level of trust in MIC values from single testing, at the cost of reduced measurement range compared to BMD.
Open AccessA multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections
Objectives Common phenotypic methods for antibiotic susceptibility testing (AST) of bacteria are slow, labour intensive and displays considerable technical variability. The QuickMIC system provides rapid AST using a microfluidic linear gradient. Here we evaluate the performance of QuickMIC at four different laboratories with regards to speed, precision, accuracy, and reproducibility in comparison to broth microdilution (BMD). Methods Spiked blood cultures (n=411) and clinical blood cultures (n=148) were tested with the QuickMIC Gram negative (GN) panel and compared with BMD for the 12 on-panel antibiotics, and 10 defined strains were run at each site to measure reproducibility. Logistic and linear regression analysis was applied to explore factors affecting assay performance. Results The overall essential agreement (EA) and categorical agreement (CA) between QuickMIC and BMD were 95.6% and 96.0%, respectively. Very major error (VME), Major error (ME) and minor error (mE) rates were 1.0, 0.6 and 2.4%, respectively. Inter-laboratory reproducibility between the sites was high at 98.9% using the acceptable standard of ±1 log2 unit. The mean in-instrument analysis time overall was 3h 13 min (SD: 29 min). Regression analysis indicated that QuickMIC is robust with regards to initial inoculate and delay time after blood culture positivity. Conclusions We conclude that QuickMIC can be used to rapidly measure MIC directly from blood cultures in clinical settings, with a high reproducibility, precision, and accuracy. The microfluidics-generated linear gradient ensures high repeatability and reproducibility between laboratories, thus allowing a high level of trust in MIC values from single testing, at the cost of reduced measurement range compared to BMD.